Clinical Trial Update: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pyrotinib in combination with fulvestrant for HER2-positive, HR-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN